Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 03, 2023

Neoadjuvant Treatment Does Not Influence PD-L1 Expression in Patients With Stage III NSCLC



Additional Info

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
ESMO Open 2023 Aug 01;8(4)101595, D König, S Savic Prince, S Hayoz, P Zens, S Berezowska, W Jochum, E Stauffer, V Braunersreuther, B Trachsel, S Thierstein, M Mark, S Schmid, A Curioni-Fontecedro, A Addeo, I Opitz, M Guckenberger, M Früh, DC Betticher, HB Ris, R Stupp, SI Rothschild, L Bubendorf, M Pless

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading